Viewing Study NCT04354961


Ignite Creation Date: 2025-12-24 @ 12:36 PM
Ignite Modification Date: 2026-02-23 @ 1:11 AM
Study NCT ID: NCT04354961
Status: UNKNOWN
Last Update Posted: 2023-11-08
First Post: 2020-04-17
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma
Sponsor: Fujian Cancer Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module